Introduction
============

Green tea has long been a daily food in Japan with beneficial health effects. Antibacterial and antitoxin effects of tea (*Camellia sinensis*) leaves are already proved in Japan in 1930s (Shimamura, [@B29]). After World War II, anti-influenza virus activity of tea extracts was published in 1949 (Green, [@B5]), and antibacterial activity of tea was published in India (Das, [@B2]). More than a quarter of a century later, antibacterial activity of tea was eventually rediscovered in 1989 (Toda et al., [@B36]). Since then, recent studies proved that polyphenol components of tea leaves have antitoxin (Hara et al., [@B6]; Toda et al., [@B37]; Hisano et al., [@B7]), antiviral (Mukoyama et al., [@B23]; Nakayama et al., [@B24]; Yamaguchi et al., [@B41]), and antitumor properties (Mukhtar et al., [@B22]; Shimamura and Hara, [@B30]) other than antimicrobial activity (Toda et al., [@B36]; Yam et al., [@B40]). Tea polyphenols have broad antibacterial spectrum, and inhibit various kinds of pathogenic bacteria such as *Bacillus cereus*, *Campylobacter* spp., *Clostridium perfringens*, *Escherichia coli* O157, *Helicobacter pylori*, *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Mycoplasma pneumonia*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Salmonella* spp., *Serratia marcescens*, *Staphylococcus* spp., oral pathogenic *Streptococci* (Friedman, [@B4]). In polyphenols, catechins belong to the flavan-3-ol class of flavonoids. Catechins are thermo stable and stable in acidic condition although those are unstable in neutral and alkali condition. (−)-Epigallocatechin-3-*O*-gallate (EGCG) is the major polyphenolic compound found in green tea and it has the strongest activity in various useful properties. However, although antiviral properties of tea polyphenols have been demonstrated also *in vivo* (Xiao et al., [@B39]), EGCG is not so useful for clinical use because of its poor membrane permeability, low chemical stability, and rapid metabolism. Previously, we synthesized a series of EGCG fatty acid monoester derivatives by lipase-catalyzed transesterification and found that addition of long acyl chains (C16--18) enhanced the anti-influenza virus activity of EGCG up to 44-fold (Mori et al., [@B21]). Acylation also enhanced the *in vitro* antitumor activities of EGCG in an alkyl chain length-dependent manner (Matsumura et al., [@B20]). Furthermore, the chemical stability of EGCG in tissue culture medium was enhanced 10-fold by acylation (Data not shown). But effects of acylation on antimicrobial and antitoxin activities of EGCG have not yet been evaluated until now. In this study, we additionally synthesized unsaturated fatty acid esters and dioctanoyl esters, and evaluated the *in vitro* activities of the acylated EGCG derivatives against a wide range of bacteria and fungi. These derivatives exhibited increased antimicrobial activities, particularly against *Staphylococcus aureus* and some fungal species. The antibacterial activity of palmitate was evaluated in detail. Taken together, these data show a potential use of EGCG *O*-acyl derivatives as novel antimicrobial agents.

Materials and Methods
=====================

Synthesis of EGCG *O*-acyl derivatives
--------------------------------------

A series of EGCG *O*-acyl derivatives (Figure [1](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}) were synthesized by lipase-catalyzed transesterification, according to a method reported previously (Mori et al., [@B21]). This method yielded B-ring-modified esters as the major products except linolenate ester (C18TE). In case of synthesis of saturated fatty acid monoesters, the ratio of regioisomers was consistent regardless of the alkyl chain length. Unsaturated fatty acid esters and dioctanoyl esters (C8 × 2) were also synthesized, and the ratio of their regioisomers is summarized in Table [1](#T1){ref-type="table"}. Mixtures of these isomers were used without isolation because they have similar chemical properties and the antiviral activities of these mixtures did not vary with their composition ratio (Mori et al., [@B21]). Log *P* values were calculated by a software; ChemBioDraw Ultra ver. 11 and used as lipophilicity index (Table [1](#T1){ref-type="table"}). Higher log *P* means higher lipophilicity. The derivatives were dissolved in DMSO and diluted with distilled water.

![**Lipase-catalyzed synthesis of EGCG fatty acid esters**. One or two of R^1--4^ are substituted with fatty acids.](fmicb-03-00053-g001){#F1}

###### 

**EGCG fatty acid esters and the ratio of their regioisomers**.

  Abbreviation           Acyl group                     Position of acyl group on EGCG fatty acid esters (%)^a^; R^1^:R^2^:R^3^:R^4^   Log *P*^c^
  ---------------------- ------------------------------ ------------------------------------------------------------------------------ ------------
  EGCG                   None                                                                                                          2.07
  C8 (octanoate)         ![](fmicb-03-00053-i001.jpg)   35:39:6:20                                                                     4.79
  C12 (laurate)          ![](fmicb-03-00053-i002.jpg)   30:39:9:22                                                                     6.46
  C8 × 2 (dioctanoate)   ![](fmicb-03-00053-i003.jpg)   ND^b^                                                                          7.50
  C16 (palmitate)        ![](fmicb-03-00053-i004.jpg)   38:35:7:20                                                                     8.13
  C16E (palmitoleate)    ![](fmicb-03-00053-i005.jpg)   28:37:9:26                                                                     7.81
  C18 (stearate)         ![](fmicb-03-00053-i006.jpg)   38:35:7:20                                                                     8.97\*
  C18E (oleate)          ![](fmicb-03-00053-i007.jpg)   41:34:5:20                                                                     8.65\*
  C18DE (linoleate)      ![](fmicb-03-00053-i008.jpg)   28:27:5:45                                                                     8.33\*
  C18TE (linolenate)     ![](fmicb-03-00053-i009.jpg)   15:19:4:62                                                                     8.01
  C20 (eicosanoate)      ![](fmicb-03-00053-i010.jpg)   28:37:9:26                                                                     9.80\*

*^a^The ratio of regioisomers was determined by ^1^H-NMR spectroscopy. ^b^The regioisomers could not be determined by ^1^H-NMR, but the product was identified by mass spectroscopy. ^c^Log *P* values were calculated using the ChemBioDraw Ultra ver. 11 software. \*The values were estimated on the basis of the log *P* values of fatty acids*.

Bacterial strains
-----------------

In total, 17 *S. aureus* strains \[9 methicillin-sensitive *S. aureus* (MSSA) and 8 methicillin-resistant *S. aureus* (MRSA) strains\]. Five MSSA and seven MRSA strains were clinically isolated from Japan (Table [2](#T2){ref-type="table"}). *E. coli* MG1655 (wild-type) and its efflux pump gene deletion mutants, Δ*acrB*, Δ*acrD*, Δ*acrEF*, and Δ*tolC* constructed by phage P1-mediated transduction (Davis et al., [@B3]; Nishino et al., [@B26]) were used to evaluate the effects of efflux pumps on the susceptibility of *E. coli* to EGCG. Moreover, standard strains of various bacterial and fungal species (Tables [3](#T3){ref-type="table"}-- [5](#T5){ref-type="table"}) were also analyzed.

###### 

**MICs of EGCG derivatives for *S. aureus***.

  Strain                               MIC: μg/ml                                                           
  ------------------------------------ ------------ ---- ---- ----- ---- ---- ---- ------- ------- -------- -------
  **MSSA**                                                                                                  
  NCTC8325                             4            8    16   16    16   16   4    128     0.125   0.008    0.25
  ATCC25923                            16           16   32   32    32   32   32   \>128   0.25    0.031    0.5
  ATCC12600                            8            16   16   32    32   16   16   \>128   0.5     0.031    0.5
  ATCC29213                            16           16   16   32    32   16   16   \>128   4       0.063    0.5
  S1[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   16   16   \>128   8       0.031    0.5
  S2[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   16   16   \>128   8       0.031    0.5
  S3[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   16   16   \>128   8       0.031    64
  S4[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   16   16   \>128   0.5     0.063    1
  S5[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   16   16   128     0.5     0.008    1
  **MRSA**                                                                                                  
  ATCC43300                            16           16   16   32    32   16   16   \>128   32      ≤0.125   \>128
  R1[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    32   32   16   \>128   64      ≤0.125   \>128
  R2[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    16   16   16   \>128   64      ≤0.125   0.5
  R3[\*](#tfn1){ref-type="table-fn"}   4            8    8    16    8    8    8    128     64      4        \>128
  R4[\*](#tfn1){ref-type="table-fn"}   16           32   64   128   64   64   64   \>128   128     \>16     \>128
  R5[\*](#tfn1){ref-type="table-fn"}   16           16   16   32    16   16   16   \>128   128     2        \>128
  R6[\*](#tfn1){ref-type="table-fn"}   32           32   64   64    64   32   64   \>128   32      \>16     \>128
  R7[\*](#tfn1){ref-type="table-fn"}   16           16   16   64    32   16   16   \>128   128     16       \>128

*\*Clinical isolates from Japan*.

###### 

**Antibacterial activities of C16 against Gram-positive bacteria**.

  Organism                                 (MIC: μg/ml)                                   
  ---------------------------------------- -------------- ------- ------- ------- ------- -------
  *Bacillus subtilis* ATCC6051             16             64      0.06    0.25    ≤0.03   0.125
  *Bacillus cereus* ATCC14579              16             64      2       64      0.06    0.5
  *Staphylococcus epidermidis* ATCC14990   8              128     0.125   0.5     0.125   1
  *Streptococcus pneumoniae* ATCC49619     16             32      ≤0.03   1       ≤0.03   0.125
  *Streptococcus pyogenes* ATCC19615       64             128     ≤0.03   0.25    ≤0.03   0.25
  *Streptococcus agalactiae* ATCC13813     \>64           \>128   ≤0.03   0.125   ≤0.03   0.25
  *Enterococcus faecalis* ATCC29212        16             256     0.25    32      2       2
  *Micrococcus luteus* ATCC9341            32             128     0.06    2       ≤0.03   0.5

Antibacterial agents and chemicals
----------------------------------

Ampicillin (AMP), amoxicillin (AMX), cefazolin (CFZ), and vancomycin (VAN) were purchased from Sigma-Aldrich Co. (St Louis, USA). Imipenem (IPM, Banyu Pharmaceutical Co., Tokyo, Japan), erythromycin (ERY, Nacalai Tesque Inc., Kyoto, Japan), teicoplanin (TEC, Astellas Pharma Inc., Tokyo, Japan), and nisin (MP Biomedicals, LLC, Illkirch, France) were also used. Fluconazole (FLC, Sigma-Aldrich Co.) was used for experiments with fungi.

Determination of MICs
---------------------

MICs were determined by the micro broth dilution method using Mueller--Hinton broth (Difco, Becton, Dickinson, and Company Japan, Tokyo, Japan) according to guidelines M07-A8 of the Clinical and Laboratory Standards Institute ([@B1]; CLSI, Wayne, PA, USA). OD~600~ was determined using a microplate reader after overnight incubation. For Figure [2](#F2){ref-type="fig"}, average and SD of OD~600~ of four wells for each concentration were calculated. RPMI 1640 medium (Sigma-Aldrich Co.) buffered with 0.165 M 3-(*N*-morpholino) propane sulfonic acid at pH 7.0 was used for fungi.

![**Acyl chain length of EGCG derivatives and their antistaphylococcal activities against MSSA ATCC25923 (A) and MRSA ATCC43300 (B)**. Mean ∓ SD of each four wells optical density (600 nm) after 18 h incubation are shown.](fmicb-03-00053-g002){#F2}

Effects of peptidoglycan from *S. aureus*, [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala, and lipopolysaccharide (LPS; all purchased from Sigma-Aldrich Co.) on the antistaphylococcal activities of C16 were evaluated by comparison of MIC with or without 30 μg/ml of each bacterial cell component according to the literature (Zhao et al., [@B47]).

The combinatorial effects of C16 or EGCG with IPM or AMP on MRSA were determined by the checkerboard method (Martinez-Irujo et al., [@B18]; Hu et al., [@B10]). The fractional inhibitory concentration (FIC) indices were calculated as follows: FIC = \[MIC~A\ in\ combination~/MIC~A\ alone~ + MIC~B\ in\ combination~/MIC~B\ alone~\]. Synergy was defined as an FIC index of less than 0.5 and addition as an FIC index of 0.5--1.0.

Determination of killing activities
-----------------------------------

Killing curves of C16 against MRSA ATCC43300, *E. coli* MG1655, and *P. aeruginosa* PAO1 were plotted and evaluated. Bacterial suspensions were diluted to approximately 1.0 × 10^5^ CFUs/ml in Mueller--Hinton broth. Bacterial counts were determined at selected time intervals of 0, 2, 4, and 6 h by enumerating the colonies formed after plating 10-fold serially diluted specimens of 100 μl aliquots on two Mueller--Hinton agar plates for each dilution; the plates were incubated at 37°C. The average numbers and SD of two to four plates were calculated.

SYTOX green uptake assay to determine membrane damage
-----------------------------------------------------

Exponentially growing cells of MSSA ATCC25923 and MRSA ATCC43300 harvested in phosphate-buffered saline were used. SYTOX Green (Lonza Walkersville, Inc., USA) is a high-affinity nucleic acid stain that can easily penetrate cells with compromised membranes but not those with intact membranes. Membrane integrity was determined after exposure to C16, EGCG or nisin for 15 min by measuring SYTOX Green uptake. Using the plate reader, fluorescence was determined (Ex/Em: 504/523 nm) after 10 min incubation with SYTOX Green in a black 384-well plate (Matsumoto et al., [@B19]). The means and SD values of triple data were calculated.

Results
=======

Relationship between acyl chain length and activities of EGCG *O*-acyl derivatives against *S. aureus*
------------------------------------------------------------------------------------------------------

Structures of the EGCG *O*-acyl derivatives and the ratio of each acyl component are listed in Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}. *S. aureus* is one of the most sensitive organisms to tea extract (Toda et al., [@B36]). The effect of acyl chain length on antistaphylococcal activity was evaluated (Figure [2](#F2){ref-type="fig"}) on the basis of the results of a previous study on antiviral activities of the acylated EGCG derivatives against influenza virus. These antiviral activities were increased in an acyl chain length-dependent manner (Mori et al., [@B21]). Growth inhibitory activities of EGCG for MSSA ATCC25923 and MRSA ATCC43300 were not increased by C8, but were increased by acyl chains longer than C12. However, these activities decreased in the derivatives with an acyl chain length longer than C18. C12 and C16 showed the strongest activity (MIC; 8 μg/ml) against both ATCC25923 and ATCC43300 strains. We then synthesized C8 × 2, C16E, C18E, C18DE, and C18TE and evaluated the effect of diacyl as well as unsaturated acyl chains against 17 *S. aureus* strains including 8 MRSA strains (Table [2](#T2){ref-type="table"}). Although most of these strains had similar sensitivities to the EGCG derivatives, some MRSA strains, particularly IPM-resistant strains, exhibited higher MICs. C8 × 2 was similar to C16 and had the strongest activity among this set of derivatives. In C18 series of derivatives, unsaturation of fatty acid moieties increased the antimicrobial activity, although this effect was not evident in C16. The log *P* values of these derivatives indicated that water solubility improved by the introduction of an unsaturated bond into C18 (Table [1](#T1){ref-type="table"}). Among the derivatives evaluated, MICs of C8 × 2 and C16 for all the 17 strains were ≤32 μg/ml, although MICs of EGCG for these strains were ≥128 μg/ml.

Antimicrobial activities of C16 against various species
-------------------------------------------------------

Antibacterial and antifungal activities of C16 are presented in Tables [3](#T3){ref-type="table"}-- [5](#T5){ref-type="table"}. Table [3](#T3){ref-type="table"} shows MICs for Gram-positive organisms other than *S. aureus*. C16 showed several-fold higher activities than EGCG against these microbial strains except *Streptococci*, against which there was less than twofold difference between MICs of both compounds. C16 exhibited 16-fold superior activities against *S. epidermidis* and *Enterococcus faecalis* than EGCG. Suppression of growth of Gram-negative bacteria was barely detected at the highest concentrations of C16 or EGCG (Table [4](#T4){ref-type="table"}), making it difficult to distinguish the differences in their activities based on their MICs. While Gram-negative bacteria tend to be insensitive to EGCG, *C. jejuni* and *H. pylori* were highly sensitive to EGCG and C16. *Neisseria meningitidis* and *N. gonorrhoeae* also exhibited sensitivity to C16.

###### 

**Antibacterial activities of C16 against Gram-negative bacteria**.

  Organism                                                   (MIC: μg/ml)                                   
  ---------------------------------------------------------- -------------- ------- ------- ------- ------- ------
  *Neisseria meningitidis[\*](#tfn2){ref-type="table-fn"}*   16             32      0.25    0.5     0.25    2
  *Neisseria gonorrhoeae* ATCC49226                          16             32      0.5     4       4       32
  *Haemophilus influenzae* ATCC49766                         \>64           \>256   0.5     2       8       \>64
  *Moraxella catarrhalis[\*](#tfn2){ref-type="table-fn"}*    64             128     0.25    0.5     0.125   64
  *Escherichia coli* ATCC25922                               \>64           \>256   8       2       64      \>64
  *Klebsiella pneumoniae* ATCC13883                          \>64           \>256   \>64    2       64      \>64
  *Klebsiella oxytoca* ATCC8724                              \>64           \>256   64      2       128     \>64
  *Citrobacter freundii* ATCC8090                            \>64           \>256   64      32      128     \>64
  *Enterobacter cloacae* ATCC13047                           \>64           \>256   \>64    \>128   \>128   \>64
  *Enterobacter aerogenes* ATCC13048                         \>64           \>256   \>64    128     128     \>64
  *Proteus mirabilis* ATCC29906                              \>64           \>256   0.5     4       \>128   \>64
  *Proteus vulgaris* ATCC13315                               \>64           \>256   16      32      \>64    \>64
  *Serratia marcescens* ATCC13880                            \>64           \>256   64      \>64    64      \>64
  *Salmonella typhimurium* IID1000                           \>64           \>256   0.5     1       64      \>64
  *Yersinia enterocolitica* ATCC9610                         \>64           \>256   4       1       32      \>64
  *Aeromonas hydrophila* ATCC7966                            \>64           \>256   \>64    32      16      \>64
  *Pseudomonas aeruginosa* ATCC7700                          \>64           \>256   \>64    \>128   128     \>64
  *Pseudomonas fluorescence* ATCC8750                        \>64           \>256   8       16      32      \>64
  *Stenotrophomonas maltophilia* ATCC13637                   \>64           \>256   \>64    128     16      \>64
  *Campylobacter jejuni* ATCC33291                           8              8       4       \>64    2       \>64
  *Helicobacter pylori* ATCC43504                            16             16      ≤0.03   0.25    0.125   \>64

*\*A clinical isolates from Japan*.

###### 

**Antifungal activities of EGCG derivatives**.

  Organism                                                  EGCG and its derivatives (MIC: μg/ml)                                      
  --------------------------------------------------------- --------------------------------------- ---- ---- ---- ---- ---- ---- ---- ------
  *Candida albicans* ATCC24433                              32                                      32   16   16   16   16   16   64   0.25
  *Candida parapsilosis* ATCC22019                          16                                      16   16   16   16   16   16   64   2
  *Candida tropicalis* ATCC750                              32                                      32   16   32   32   32   16   64   2
  *Candida krusei* ATCC6258                                 16                                      16   16   16   16   16   16   64   32
  *Candida glabrata* ATCC90030                              16                                      16   16   16   16   32   32   32   16
  *Cryptococcus neoformans* ATCC90112                       16                                      8    8    16   16   8    8    64   1
  *Aspergillus fumigatus[\*](#tfn3){ref-type="table-fn"}*   32                                      32   16   32   32   32   16   64   \>64

*\*A clinical isolate from Japan*.

Antifungal activity of EGCG and its acyl derivatives were evaluated against various species of *Candida*, *Cryptococcus neoformans*, and *Aspergillus fumigatus* (Table [5](#T5){ref-type="table"}). MICs of the derivatives for these fungi were two to fourfold superior to those of EGCG. C16E exhibited the highest activities against these fungi. Introduction of unsaturated bonds into the acyl chain tended to increase the antifungal activities of the derivatives.

Killing activities of C16
-------------------------

The rapid bactericidal activity of tea extracts against *S. aureus* are known through research on the antibacterial activities of catechins (Toda et al., [@B36]). A time-kill study was conducted against MRSA ATCC43300, *E. coli* MG1655, and *P. aeruginosa* PAO1 (Figure [3](#F3){ref-type="fig"}). C16 demonstrated rapid bactericidal activity against MRSA at ≥16 μg/ml. However, 128 μg/ml of C16 only showed bacteriostatic activity against *E. coli* MG1655 and *P. aeruginosa* PAO1.

![**Killing activity of C16 against MRSA ATCC43300 (A), *E. coli* MG1655 (B), and *P. aeruginosa* PAO1 (C)**. Cells were incubated with C16 in Muller--Hinton broth at 37°C on a shaker. Residual cells after 2, 4, and 6 h incubation were counted as colonies grown on the Mueller--Hinton agar plates. Mean ∓ SD of the residual CFUs calculated from two to four plates are shown.](fmicb-03-00053-g003){#F3}

Combinatorial effects of C16 on antibacterial activity of β-lactams in the checkerboard method
----------------------------------------------------------------------------------------------

The synergistic effects of EGCG with β-lactams have been well described (Hu et al., [@B10], [@B8]). C16 and EGCG were evaluated in combination with IPM or AMP against MRSA strains (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). We used two MRSA strains, IPM-sensitive ATCC43300 and IPM-resistant clinical isolate R3. C16 enhanced the activities of IPM and AMP against both MRSA strains (Figure [4](#F4){ref-type="fig"}); the FIC indices were 0.5--1.0. On the other hand, EGCG exhibited negative activity with IPM against IPM-sensitive ATCC43300 (Figure [5](#F5){ref-type="fig"}A), although synergy between EGCG and IPM (FIC index \< 0.07) against IPM-resistant strain R3 was remarkable (Figure [5](#F5){ref-type="fig"}B). EGCG also showed pronounced synergistic activity with AMP against both MRSA strains (FIC indices \<0.188; Figures [4](#F4){ref-type="fig"}C,D). In other words, MIC of IPM for R3 was decreased by 8 μg/ml EGCG from \>4 to 0.063 μg/ml, whereas 8 μg/ml of C16 inhibited the growth of R3 by itself. C16 and EGCG exhibited negative activity with IPM or AMP against MSSA (data not shown) which was similar to that shown in Figure [5](#F5){ref-type="fig"}A.

![**Combinatorial effects of C16 with IPM (A,B) or AMP (C,D) against MRSA strains**. Optical densities (600 nm) after 18 h incubation were determined by the checkerboard method.](fmicb-03-00053-g004){#F4}

![**Combinatorial effects of EGCG with IPM (A,B) or AMP (C,D) against MRSA strains**. Optical densities (600 nm) after 18 h incubation were determined by the checkerboard method.](fmicb-03-00053-g005){#F5}

Effect of peptidoglycan on antistaphylococcal activity of C16
-------------------------------------------------------------

The bactericidal activity of EGCG against *S. aureus* was blocked by the purified peptidoglycan (Yoda et al., [@B43]). Effects of peptidoglycan, [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala, and LPS, on the activity of C16 against MSSA ATCC25923 and MRSA ATCC43300 were determined by changes in MIC caused by the addition of each component to the medium (Table [6](#T6){ref-type="table"}). MICs of C16 for both bacterial strains were reproducible and doubled in the presence of peptidoglycan as well as MICs of glycopeptide, VAN, and TEC. However MICs of C16 did not change with the addition of [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala or LPS. In contrast, MICs of VAN and TEC increased 8- and 32-fold respectively, with the addition of [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala, the target molecule of glycopeptides in cell walls.

###### 

**Effect of peptidoglycan, [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala, and lipopolysaccharide on antistaphylococcal activity of C16**.

  Agents   ATCC25923 (MIC: μg/ml)   ATCC43300 (MIC: μg/ml)                                  
  -------- ------------------------ ------------------------ -------- ------ ----- -------- --------
  C16      16                       **32**                   16       16     8     **16**   8
  VAN      2                        **4**                    **16**   2      1     **2**    **16**
  TEC      1                        **2**                    **32**   1      0.5   **1**    **16**
  AMP      0.25                     0.25                     0.25     0.25   16    8        16

*Staphylococcus aureus ATCC25923 and methicillin-resistant S. aureus ATCC43300 were used. PG, peptidoglycan; [d]{.smallcaps}-Ala, [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala; LPS, lipopolysaccharide. Bold letters indicate increased MICs versus control*.

Effect of efflux pump deletion on activities of EGCG *O*-acyl derivatives in *E. coli*
--------------------------------------------------------------------------------------

Efflux pumps are major resistant factors in Gram-negative bacteria (Poole et al., [@B28]; Nikaido, [@B25]; Li and Nikaido, [@B17]). *E. coli* has several pumps that effect drug resistance (Nishino and Yamaguchi, [@B27]). Effects of deletion of genes associated with three of these pumps, AcrAB--TolC, AcrCD--TolC, and AcrEF--TolC were evaluated. AcrAB--TolC is the most powerful pump that is constitutively expressed in *E. coli* and has a broad substrate profile (Nishino and Yamaguchi, [@B27]). To evaluate the possibility of EGCG and its derivatives to act as a substrate for efflux pumps, MICs of the EGCG derivatives for efflux pump gene deletion mutants of *E. coli* MG1655 were determined (Table [7](#T7){ref-type="table"}). MICs of all tested derivatives and EGCG for Δ*acrB* and Δ*tolC* were lower than those for the wild-type strain. The *acrD* or *acrEF* deletion had almost no effect on the activities of the EGCG derivatives against *E. coli*. EGCG and its acyl derivatives were considered to be substrates for AcrAB--TolC. Susceptibility of Δ*tolC*, a mutant in which all TolC-dependent pumps are inactive, to the C8 × 2 was fourfold higher than that to EGCG.

###### 

**Activities of EGCG derivatives against efflux pump gene deletion mutants of *E. coli***.

  Strains              EGCG and its derivatives (MIC: μg/ml)                           
  -------------------- --------------------------------------- ------- ------- ------- -------
  MG1655 (Wild-type)   \>128                                   \>128   \>128   \>128   \>256
  Δ*acrB*              64                                      64      64      64      128
  Δ*tolC*              32                                      64      64      64      128
  Δ*acrD*              \>128                                   \>128   \>128   \>128   \>256
  Δ*acrEF*             \>128                                   \>128   \>128   \>128   \>256

*Escherichia coli MG1655 and its efflux pump gene deletion mutants were used*.

Membrane damage determined by SYTOX green uptake assay
------------------------------------------------------

The bacterial membrane is considered to be one of the most effective targets of catechins (Kajiya et al., [@B13]). The membrane-disrupting activities of C16 were compared with those of EGCG in MSSA ATCC25923 and MRSA ATCC43300 (Figure [6](#F6){ref-type="fig"}). Under this condition, a polycyclic antibacterial peptide nisin at 1 μg/ml significantly increased SYTOX Green uptake in both bacterial strains. In a concentration-dependent manner, C16 increased SYTOX Green uptake at ≥8 μg/ml (a half of MIC) after 15 min incubation with *S. aureus* cells, while EGCG did not induce SYTOX Green uptake at 128 μg/ml. EGCG at 64 μg/ml actually exhibited a protective effect; SYTOX Green uptake was less than a half of the dye uptake observed with controls. C16 disrupted the membrane of *S. aureus* more effectively than EGCG, which supports the previously observed low MIC of C16 for *S. aureus*.

![**Membrane damage caused by C16 determined by SYTOX Green uptake assay**. Fluorescence was determined (Ex/Em: 504/523 nm) after 10 min incubation with SYTOX Green in a black 384-well plate using a microplate reader after incubation with the antimicrobial compound for 15 min. Fluorescence is shown as a ratio to that of control. Data represent Mean ∓ SD (*n* = 3). \*A polycyclic antibacterial peptide.](fmicb-03-00053-g006){#F6}

Discussion
==========

*Staphylococcus aureus* is one of the most sensitive bacteria to tea polyphenols. The rapid bactericidal activity of tea extracts against *S. aureus* was demonstrated in 1989 (Toda et al., [@B36]), and the mechanism underlying the killing activity of catechin by disrupting the lipid bilayer of the membrane (Ikigai et al., [@B11]). Subsequently, interaction of catechin with lipid bilayers has been studied in detail (Kumazawa et al., [@B16]; Uekusa et al., [@B38]; Kajiya et al., [@B14]; Kamihira et al., [@B15]; Sirk et al., [@B32], [@B31], [@B33]; Sun et al., [@B35]). Previously, Kajiya et al. synthesized (+)-Catechin derivatives with different alkyl chain lengths and found the antibacterial activity increased markedly with elongation of the alkyl chain lengths of the derivatives and reached a maximum at a chain of four to seven carbons. Lipophilicity and the membrane-disrupting ability of these derivatives correlate with their antibacterial activities against Gram-positive organisms (Kajiya et al., [@B13]). In our study, addition of acyl chains longer than C12 to EGCG significantly enhanced its antibacterial activities particularly against *S. aureus* including MRSA. However, the activity of EGCG *O*-acyl derivatives decreased in the derivatives with an acyl chain length longer than C18, so that C12 and C16 had the highest activity against *S. aureus* (Figure [2](#F2){ref-type="fig"}). MICs of C8 × 2 for the 17 *S. aureus* strains were the lowest and comparable to those of C16 (Table [2](#T2){ref-type="table"}). The increased activities of these derivatives against *S. aureus* are probably a result of their enhanced affinity of their long acyl chains to interact with membranes. In fact, 8 μg/ml of C16 showed significant membrane-permeabilizing activity in *S. aureus*. On the other hand, EGCG inhibited SYTOX Green uptake to less than a half of the control at 64 μg/ml (Figure [6](#F6){ref-type="fig"}). As an explanation of the opposite effect of 64 μg/ml EGCG in SYTOX Green uptake assay, peptidoglycan-binding activity of EGCG could be higher than its affinity to membrane and interfered penetration of SYTOX Green into Staphylococcal cells. SYTOX Green would be permeabilized by EGCG in concentrations higher than its MIC. Against influenza virus, C16 also exhibited the strongest activity, suggesting an interaction with the viral membrane (Mori et al., [@B21]); however, the derivatives with acyl chains longer than 16 exhibited decreased activities probably because of their decreased solubility. The role of decreased solubility as being a possible reason was deduced from the higher lipophilicity speculated from the higher log *P* values in C18 and C20 (Table [1](#T1){ref-type="table"}). Introduction of an unsaturated bond into the acyl chain tended to reduce lipophilicity and recover the activity, although it was not very effective in C16 (Table [2](#T2){ref-type="table"}). Anyway, influenza virus is more sensitive to C16 than *S. aureus* and *E. coli*. The effect of acyl chain length on antistaphylococcal activity of EGCG was similar but not coincident with that on anti-influenza virus activity of it. The difference might come from the different surface structure of these pathogens such as cell wall in *S. aureus* rather than common lipid bilayer. Outer membrane and cell wall of bacteria might protect lipid bilayer from polyphenols. Acylation might possible to enhance interaction of EGCG with lipid bilayer but not break through outer membrane.

Synergistic activities of EGCG with β-lactams against MRSA have been studied previously (Hu et al., [@B10], [@B8]). Contemporary, EGCG is shown to have no effect on penicillin-binding protein 2′ (PBP2′; protein causative of methicillin-resistance in MRSA) mRNA expression or PBP2′ production (Zhao et al., [@B47]). In combinatorial effects with other cell wall synthesis inhibitors, EGCG also enhance activity of [dl]{.smallcaps}-cycloserine (Zhao et al., [@B47]), but antagonizes the activity of VAN and TEC against MRSA (Hu et al., [@B9]). Furthermore, EGCG antagonizes the activity of polymyxin B against *E. coli* (Hu et al., [@B9]). EGCG interferes with cell wall integrity by directly binding to peptidoglycan, and this might be the major reason for the synergism between EGCG and β-lactams. EGCG might also bind directly to glycopeptides and then interfere with their activities (Hu et al., [@B9]). In our results, C16 activity against *S. aureus* was decreased with the addition of peptidoglycan, but not of [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala (Table [6](#T6){ref-type="table"}), which indicates that C16 binding to peptidoglycan occurs because of some peptidoglycan structural moieties other than [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala. The peptidoglycan-binding ability of C16 without a [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala-mediated mechanism could adversely affect its antibacterial activity against *S. aureus*. In fact, 64 μg/ml of EGCG decreased SYTOX Green uptake in *S. aureus* (Figure [5](#F5){ref-type="fig"}), which indicates a potential protective effect of EGCG on the surface of bacteria. Binding of EGCG to peptidoglycan might interfere with binding of glycopeptides to [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala residue. In addition, EGCG inhibits the activity of various β-lactamases not only from *S. aureus* but also from Gram-negative bacteria, including carbapenem-hydrolyzing enzyme, IMP-1 (Zhao et al., [@B46], [@B45]). However, most cephalosporins and carbapenems are stable against penicillinase from *S. aureus*. For this reason, β-lactamase-inactivating activity of EGCG cannot explain the mechanism of synergistic activity between EGCG and IPM against MRSA. When we focus on the action mechanism of β-lactam, there are four different cell wall synthesizing enzymes in *S. aureus*. PBP2′ alone might not completely fulfill the functions of these other intrinsic *S. aureus* PBPs (Zapun et al., [@B44]). Actually, synergism between carbapenems and other β-lactams having different PBP affinities against MRSA has also been reported (Sumita and Mitsuhashi, [@B34]). Cell wall synthesis partially affected by β-lactam would provide an easy access for EGCG to the membrane of MRSA. In contrast, C16 appears to access the membrane more easily than EGCG (Figure [6](#F6){ref-type="fig"}). Therefore, the combinatorial effect of β-lactam with C16 against MRSA might be weak. In fact, the combinatorial effects of C16 with AMP and IPM (Figure [3](#F3){ref-type="fig"}) were mostly within additive category (FIC indices \>0.5), and were not as strong as those of EGCG with AMP (Figure [5](#F5){ref-type="fig"}).

Different EGCG susceptibility of *Staphylococci* and Gram-negative rods are observed due to the different EGCG affinities toward various cell wall components (Yoda et al., [@B43]). EGCG activity against Enterobacteriaceae was weak and was not strongly enhanced by acylation (Table [4](#T4){ref-type="table"}); however, we did detect higher activity of the EGCG fatty acid derivatives compared to EGCG against *acrB* or *tolC* deletion mutants of MG1655 (Table [7](#T7){ref-type="table"}). AcrAB--TolC can export various compounds with very different structures (Nishino and Yamaguchi, [@B27]). EGCG and its derivatives are now identified as substrates for AcrAB--TolC. Efflux and low outer membrane permeability could be a strong reason for the weaker activity of EGCG against Gram-negative bacteria such as *E. coli*. In higher concentrations, tea polyphenols can inhibit the growth of *P. aeruginosa* by permeabilizing its membrane (Yi et al., [@B42]). In this study, 64 μg/ml of C16 inhibited the growth of *P. aeruginosa* PAO1, although it was not bactericidal (Figure [3](#F3){ref-type="fig"}).

Acylation of EGCG enhanced its antimicrobial activity against various species of bacteria and fungi although it did not expand antibacterial spectrum (Tables [2](#T2){ref-type="table"}-- [5](#T5){ref-type="table"}). C8 × 2 and C16 had the strongest activity against bacteria, particularly against *S. aureus* including MRSA. Moreover, C16 is proved to have superior activity including antivirus (Mori et al., [@B21]; Kaihatsu et al., [@B12]) and antitumor (Matsumura et al., [@B20]) activities. Although effect of acylation on antitoxic property of EGCG is not yet evaluated, beneficial effect would not be expected on that because toxins are usually not associated with membrane. These findings are exciting and further research may support the finding that the broad activity of C16 could be invaluable for clinicians as an alternative disinfectant as well as an alternative treatment option to antibiotics, perhaps reducing the risk of antibiotic resistance.
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